Skip to main content

Table 1 Definitions of Percent Specific Binding Used in Radioimmunoprecipitation Assays

From: Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies

Assay Percent specific binding definition
MYL-1501D Total ADA %B/T (no inhibitor) − %B/T (excess MYL-1501D)
Insulin cross-reactive ADA %B/T (no inhibitor) − %B/T (excess insulin)
Drug-specific ADA %B/T (excess IGlar) − %B/T (excess MYL-1501D)
IGlar Total ADA %B/T (no inhibitor) − %B/T (excess reference insulin glargine)
Insulin cross-reactive ADA %B/T (no inhibitor) − %B/T (excess insulin)
Drug-specific ADA %B/T (excess MYL-1501D) − %B/T (excess IGlar)
  1. ADA antidrug antibodies, %B/T percentage of bound to total reactivity, IGlar insulin glargine